A new solution once again has been considered to help prolong the lives and helps with the survival of those suffering from ovarian cancer. This so called heart drug is called a beta blocker, which was originally given to treat other issues with regards to high blood pressure or other heart diseases. A study was raised within 1,425 women who took the said drug of the certain type have lived much longer than those who wasn't prescribed with the beta blocker.
This study was "retrospective and thus wasn't randomized" and under strict limitations. More research is being done as of the current time. According to Anil K. Sood, a senior researcher and professor at the University of Texas M.D. Anderson Cancer Center in Houston, a study over the previous years has been launched in regards with the effects of chronic stress and sustained adrenergic activation have on cancer growth. Their research resulted in a discovery that beta-2 and beta-3 adrenergic are present on ovarian cancer cells and have an important role in promoting the formation and differentiation of blood vessels and on the survival of cancer cells.
As of now, ovarian cancer is considered the 5th deadliest cancer for women. A disquisition in the U.S. predicted that about 21,000 will be diagnosed with ovarian cancer and more than 14,000 will die from it, with the high recurrence and chemotherapy.
A clinical director, Christina M. Annunziata, from Center for Cancer Research at the National Institutes of Health, said that the study has been very interesting though it's not practice-changing yet. Even though she wasn't directly involved with the study, she is a co-author of the editorial that was published in the journal of the American Cancer Society, wrote that "This study lays the groundwork for insightful investigation into repurposing cardiovascular medications to cancer therapeutics."
